🤓 Just 1 week into 2025: These 7 AI-picked stocks are up +9% eachUnlock Stocks

Newly Published Review Highlights the Pivotal Role of Daxor's Blood Volume Analysis Technology in Advancing Cardiorenal Syndrome Management

Published 09/12/2024, 12:40 PM

DXR
3.46%

Review Published in the Prestigious Journal Cardiorenal Medicine

Oak Ridge, TN, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Daxor (NASDAQ:DXR) Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a review published in the journal Cardiorenal Medicine that delves into the intricate landscape of cardiorenal syndrome (CRS) and highlights the pivotal role of Blood Volume Analysis (BVA) in improving patient care and outcomes.

Key findings:

  • BVA as a diagnostic tool enhances the precision of diuretic and red cell therapies, significantly elevating the effectiveness of conventional care.
  • Integrating BVA in CRS care has clinical implications, including personalized treatment and improved outcomes.
  • The heart-kidney relationship in CRS underscores the need for precise, personalized care, where BVA plays a crucial role.

The review titled, Blood Volume Analysis and Cardio-renal syndrome: from bench to bedside, explored the relationship between the heart and kidneys in CRS and discussed the usage of BVA in assessing and managing this challenging syndrome. Expert contributors included John Lynn Jefferies, MD, MBA, MPH, FACC, FAHA, FAAP, FHFSA, FRCPE, FESC, Cynthia Ann Stavish, MSN, APRN, ACNS-BC, PHN, Marc A. Silver, MD, FACC, FAHA, FHFSA, Javed Butler, MD, MPH, MBA, Harvey David Humes, MD, and John Strobeck, MD, PhD, FACC.

CRS involves the complex interplay of cardiac and renal dysfunction said John L. Jefferies, MD, Daxor's Chief Medical Officer. BVA is a highly accurate (98%) technique for measuring total blood and red blood cell volumes, informing the evaluation and treatment of CRS, including its subtypes, pathophysiology, and clinical significance. Integrating BVA into CRS management optimizes personalized therapy and enhances patient outcomes.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.

By 2030, the CRS patient population is projected to reach 47 million, significantly impacting healthcare costs," said Michael Feldschuh, CEO and President of Daxor. "Our BVA technology provides clinicians with actionable data to optimize and personalize treatment plans, improving outcomes while reducing care duration and costs."

Access the Review HERE.

About Daxor Corporation

Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100 ® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor's vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor's innovative technology HERE.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.

Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com



Should you invest $2,000 in DXR right now?

Before you buy stock in DXR, consider this: ProPicks AI are 6 easy-to-follow model portfolios created by Investing.com for building wealth by identifying winning stocks and letting them run. Over 150,000 paying members trust ProPicks to find new stocks to buy – driven by AI. The ProPicks AI algorithm has just identified the best stocks for investors to buy now. The stocks that made the cut could produce enormous returns in the coming years. Is DXR one of them?

Reveal Undervalued Stocks Now

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.